MDS & Myeloproliferative Neoplasms

MDS & Myeloproliferative Neoplasms

A collection of features and news articles published in ASH Clinical News related to myelodysplastic syndromes and myeloproliferative neoplasms.

Perspectives on 2019’s New Hematology Drug Approvals

In 2019, the FDA approved several new therapies – or new indications for previously approved therapies – for people living with blood disorders, including...

Adding Navitoclax to Ruxolitinib in Ruxolitinib-Refractory Myelofibrosis Leads to Improvements in Spleen Volume, Symptom...

Watch our interview with Jacqueline Garcia, MD. More than one-third of patients with myelofibrosis (MF) who had not responded adequately to monotherapy with the FDA-approved...

Jacqueline Garcia: Evaluating Navitoclax for Myelofibrosis

Jacqueline S. Garcia, MD, shares results from a phase II study of navitoclax, an investigational disease-modifying therapy for the treatment of myelofibrosis, which appears...

Bomedemstat Reduces Symptom Burden for Patients With Myelofibrosis

Bomedemstat improved symptoms in most patients with myelofibrosis, with no dose-limiting toxicities or progressions to acute myeloid leukemia, according to results from the first...

Uma Borate: Evaluating MBG453 in High-Risk MDS and AML

Combining MBG453 with hypomethylating agents was "extremely well tolerated," with no high-grade immune-related toxicities. Uma Borate, MD, discusses the safety and preliminary efficacy data.

Aaron Gerds: What Does the Future Hold for Pacritinib?

Aaron Gerds, MD, MS, shares results from the PAC203 trial, which enrolled patients with high-risk and heavily refractory myelofibrosis.
WIB_icon

Pegylated Interferon Leads to High Response Rates in Essential Thrombocythemia and Polycythemia Vera After...

According to results of a phase II study published in Blood, treatment with pegylated-interferon-α (PEG-rIFN-α) was associated with an overall response rate (ORR) of...
You Make the Call

From ASH Meeting on Hematologic Malignancies: How would you treat this patient with high-grade...

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
WIB_icon

Estimated Prevalence of JAK2 V617F Mutations High in General Danish Population

The driver mutation JAK2 V617F and Calreticulin (CALR) mutations constitute major diagnostic criteria of myeloproliferative neoplasms (MPNs), and, while JAK2 V617F has been detected...

Fedratinib Now Approved for Primary or Secondary Myelofibrosis

The U.S. Food and Drug Administration (FDA) has approved fedratinib to treat intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis....
Advertisement

Current Issue

January 2020 Annual Meeting Edition

This issue features highlights from the 2019 ASH Annual Meeting, reflections on physician wellness, and more.